A5024553298- Prostate Cancer Treatment and Research
- Organ Transplantation Techniques and Outcomes
- Renal Transplantation Outcomes and Treatments
- Organ Donation and Transplantation
- Prostate Cancer Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Neurological Complications and Syndromes
- Renal cell carcinoma treatment
- Pharmacological Effects and Toxicity Studies
- Radiopharmaceutical Chemistry and Applications
- Renal and Vascular Pathologies
- Bone health and treatments
- Hematological disorders and diagnostics
- Cancer, Hypoxia, and Metabolism
- Virus-based gene therapy research
- Cancer, Lipids, and Metabolism
- Renal function and acid-base balance
- Cytomegalovirus and herpesvirus research
- Bipolar Disorder and Treatment
- Heterotopic Ossification and Related Conditions
- Macrophage Migration Inhibitory Factor
- Trypanosoma species research and implications
- Pneumocystis jirovecii pneumonia detection and treatment
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
Hospital de São José
2024
Pontificia Universidad Católica de Chile
2001-2011
The University of Texas MD Anderson Cancer Center
1999-2011
Roswell Park Comprehensive Cancer Center
2011
Sarah Cannon
2006
Memorial Sloan Kettering Cancer Center
2006
Dana-Farber Cancer Institute
2006
Mayo Clinic in Arizona
1994
The Association of Directors Anatomic and Surgical Pathology has developed Recommendations for the Reporting Common Malignant Tumors. Neoplasms Prostate are reported herein.
Our recent genome-wide allelotyping analysis of gallbladder carcinoma identified 3p, 8p, 9q and 22q as chromosomal regions with frequent loss heterozygosity. The present study was undertaken to more precisely identify the presence location allele involving those chromosomes in carcinoma. Microdissected tissue from 24 were analysed for PCR-based heterozygosity using 81 microsatellite markers spanning chromosome 3p (n=26), 8p (n=14), (n=29) (n=12) regions. We also studied role losses...
4501
Vascular calcification has been widely recognized as a significant contributor to cardiovascular risk in patients with chronic kidney disease. Recent evidence suggests that BMP-7 decreases the vascular observed uraemic rats, while BMP-2 could also be participating this process. Gremlin, bone morphogenetic protein antagonist, detected rat aortic smooth muscle cells (VSMCs), and since role of VSMCs into uraemia is considered critical process, we hypothesized gremlin its pathogenesis. With aim,...
4562 Background: To further examine preclinical (Uehara, JNCI 2003) and clinical (Mathew, JCO 2004) evidence that the platelet-derived growth factor receptor (PDGFR) inhibitor, Imatinib, may modulate taxane activity in AIPC with BM, a randomized trial was conducted. Methods: 144 men progressive no prior taxane, ECOG Performance Score (PS) ≤ 2, stratified by PS, hemoglobin, alkaline phosphatase number of regimens, were planned for equal randomization to i.v. Docetaxel 30mg/m 2 D 1, 8, 15, 22...
143 Background: Presurgical ADT does not improve long-term outcomes in patients (pts) with high-risk localized PCa. Since the VEGF and PDGF signaling pathways have been implicated PCa progression, results endothelial cell apoptosis prostate by a VEGF-mediated mechanism, we hypothesized that combined treatment sunitinib malate (SU), an oral inhibitor of tyrosine kinases VEGFR PDGFR, might efficacy this pt population. Methods: Pts no radiological evidence metastases either ≥ clinical (c)T3...
To report a pediatric case of drug-induced thrombotic microangiopathy caused by cocaine.We nine-month-old patient who developed microangiopathies after extreme cocaine intoxication, multiple organ dysfunction syndrome with hemodynamic dysfunction, anuric renal failure, liver encephalopathy, and myocardial injury, corresponding phenotypically to thrombocytopenia-associated failure. The received continuous venous hemofiltration therapeutic plasma exchange, recovering satisfactorily. She was...
16004 Background: Presurgical androgen deprivation therapy (ADT) does not improve long-term outcomes in patients (pts) with high- risk localized prostate cancer (PCa). Sunitinib malate (SU) is an oral inhibitor of the tyrosine kinases VEGFRs, PDGFRs, KIT, FLT3, CSF-1R and RET. Since VEGF PDGF signaling pathways have been implicated angiogenesis PCa progression, ADT results endothelial cell apoptosis by a VEGF-mediated mechanism, we hypothesized that combined treatment SU might efficacy this...
5017 Background: Responses to the CYP 17 inhibitor, AA, confirm therapeutic significance of persistent androgen signaling in CRPC. Elucidating source residual androgens and validation predictive markers will lead individualized deprivation therapy Methods: We performed an exploratory study screen for associations between serum (endocrine) microenvironment (paracrine) concentration response AA. Study pts had bone metastases a BM biopsy. Pts received oral AA 1,000mg QD prednisone 10mg have...
4666 Background: Small cell prostate cancer (SCPC) predicts for resistance to androgen ablation, frequent response platinum-based chemotherapy, but short survival. We hypothesize that PCa patients who share clinical features with SCPC (Table) are morphologically heterogeneous its high responsiveness chemotherapy and underlying biology. Methods: Men anaplastic were treated frontline CD (C:AUC 5 D:75mg/m2 Q21days) followed, at disease progression (PD), by salvage EP (E:120mg/m2/day...